ArticlePloS one2011
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Anti-Cancer Effect ofReports of biochemistry & molecular biology · 2023Article
- Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety.International journal of molecular sciences · 2022Article
- Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism-Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers?International journal of molecular sciences · 2019Review
- Novel Imaging in Detection of Metastatic Prostate Cancer.Current oncology reports · 2019Review
- Response of Cisplatin Resistant Skov-3 Cells to [Pt(Molecules (Basel, Switzerland) · 2018Article
- Prostate cancer diagnosis and characterization with mass spectrometry imaging.Prostate cancer and prostatic diseases · 2018Review
- Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.Oncotarget · 2018Article
- Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones.Scientific reports · 2017Article
- Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.Metabolites · 2017Review
- Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors.Oncotarget · 2017Article
- Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism.NPJ precision oncology · 2017Article
- Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.Translational oncology · 2016Review
- Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.Frontiers in oncology · 2016Review
- In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.Frontiers in oncology · 2016Review
- A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.British journal of cancer · 2015Article
- Metabolic reprogramming in mutant IDH1 glioma cells.PloS one · 2015Article
- HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer.NMR in biomedicine · 2014Article
- MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.NMR in biomedicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Targeted therapeutic approaches are increasingly being implemented in the clinic, but early detection of response frequently presents a challenge as many new therapies lead to inhibition of tumor growth rather than tumor shrinkage. Development of novel non-invasive methods to monitor response to treatment is therefore needed. Magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopic imaging are non-invasive imaging methods that can be employed to monitor metabolism, and previous studies indicate that these methods can be useful for monitoring the metabolic consequences of treatment that are associated with early drug target modulation. However, single-metabolite biomarkers are often not specific to a particular therapy. Here we used an unbiased 1H MRS-based metabolomics approach to investigate the overall metabolic consequences of treatment with the phosphoinositide 3-kinase inhibitor LY294002 and the heat shock protein 90 inhibitor 17AAG in prostate and breast cancer cell lines. LY294002 treatment resulted in decreased intracellular lactate, alanine fumarate, phosphocholine and glutathione. Following 17AAG treatment, decreased intracellular lactate, alanine, fumarate and glutamine were also observed but phosphocholine accumulated in every case. Furthermore, citrate, which is typically observed in normal prostate tissue but not in tumors, increased following 17AAG treatment in prostate cells. This approach is likely to provide further information about the complex interactions between signaling and metabolic pathways. It also highlights the potential of MRS-based metabolomics to identify metabolic signatures that can specifically inform on molecular drug action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.